Asset profile
ribupatide
Peptide
Evidence outlook · lead readout
NCT06650007 · Type 2 Diabetes
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT06650007: This was a randomized, double-blind, placebo-controlled trial with 218 participants, using change in HbA1c as the primary measure. A company update reports a mean HbA1c reduction of up to 2.67 percentage points with once-weekly ribupatide compared with placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Atherosclerotic Cardiovascular Disease · Phase 3Obesity · Phase 3Heart Failure · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
232 competitors in this universe: 11 direct rivals (same mechanism and indication), 1 same-class, 220 same-indication; 66 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ribupatide: this drug | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Tirzepatide (Zepbound / Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | ||
| BGM0504 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Brenipatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Enicepatide | Phase 3 | Peptide | GLP-1 receptor, GLP-1/GIP receptor (dual) | ||
| HDM1005 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| HS-20094 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| RAY1225 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| VK2735 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| NNC0519-0130 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| Olatorepatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| THDBH120 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| KP405 | Phase 1 | Peptide | GLP-1/GIP receptor (dual) | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 |
…and 217 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
2027 (7)
January 2027 (1)
February 2027 (2)
March 2027 (1)
What to watch
May 2027 (2)
October 2027 (1)
What to watch
2028 (6)
February 2028 (2)
March 2028 (3)
What to watch
November 2028 (1)
What to watch
2031 (1)
May 2031 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.